Drugs News and Research

RSS

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid.

23 Mar 2015

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis.

23 Mar 2015

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, today announced top-line data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS).

23 Mar 2015

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).

23 Mar 2015

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.

23 Mar 2015

Saccharin could potentially lead to development of drugs for difficult-to-treat cancers

Saccharin, the artificial sweetener that is the main ingredient in Sweet 'N Low, Sweet Twin and Necta, could do far more than just keep our waistlines trim. According to new research, this popular sugar substitute could potentially lead to the development of drugs capable of combating aggressive, difficult-to-treat cancers with fewer side effects.

23 Mar 2015

Acne patients not getting medications prescribed by their dermatologists

Medicine obviously can't do much good if it sits on a pharmacy shelf. Yet more than one-quarter of the acne patients surveyed by Wake Forest Baptist Medical Center researchers didn't get medications prescribed by their dermatologists.

23 Mar 2015

Genetic flaws in bowel cancer may trigger immune response at site of tumours

Scientists have found that genetic changes in bowel tumours are linked to the way the body's immune system responds to the cancer, according to research published today (Monday) in the journal Oncoimmunology.

23 Mar 2015

Study explains why generic insulin remains out of reach for diabetes patients

A generic version of insulin, the lifesaving diabetes drug used by 6 million people in the United States, has never been available in this country because drug companies have made incremental improvements that kept insulin under patent from 1923 to 2014.

23 Mar 2015

UM experts warn of serious risks associated with common IV devices

Every day, patients around the country get IV devices placed in their arms, to make it easier to receive medicines or have blood drawn over the course of days or weeks. But these PICC lines, as they're called, also raise the risk of potentially dangerous blood clots.

23 Mar 2015

How our DNA may prevent bowel cancer

The link between taking aspirin, and similar medications called non-steroidal anti-inflammatory drugs (or NSAIDS), and bowel (colorectal) cancer prevention is well established.

23 Mar 2015

Appriss partners with The MetroHealth System to fight drug abuse

Appriss Inc., a leading technology provider for risk assessment and analytics in public safety and healthcare, announced its partnership with The MetroHealth System in Ohio to fight drug abuse, diversion and addiction where it's needed most – at the prescribing level.

23 Mar 2015

Existing drugs could help prevent deadly familial stomach and lobular breast cancers

Deadly familial stomach and lobular breast cancers could be successfully treated at their earliest stages, or even prevented, by existing drugs that have been newly identified by cancer genetics researchers at New Zealand's University of Otago.

23 Mar 2015

Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

Late stage pancreatic cancer benefits from photodynamic therapy (PDT) but the resources needed for the usual accompanying dosimetry present barriers, Dartmouth researchers Jonathan T. Elliott, PhD and Brian C. Pogue, PhD have mitigated by using common clinical technologies.

23 Mar 2015

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO).

23 Mar 2015

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.

23 Mar 2015

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding--as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.

23 Mar 2015

Drugs News and Research

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Saccharin could potentially lead to development of drugs for difficult-to-treat cancers

Acne patients not getting medications prescribed by their dermatologists

Genetic flaws in bowel cancer may trigger immune response at site of tumours

Study explains why generic insulin remains out of reach for diabetes patients

UM experts warn of serious risks associated with common IV devices

How our DNA may prevent bowel cancer

Appriss partners with The MetroHealth System to fight drug abuse

Existing drugs could help prevent deadly familial stomach and lobular breast cancers

Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Discovery may lead to new potential treatment for drug-resistant melanoma

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Thomson Reuters releases 2015 edition of annual Drugs to Watch report

Eli Lilly, Innovent Biologics announce biotech drug development collaborations in China

WHO calls for intensification of routine immunization services in all Ebola-affected areas

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News